UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

Zev A. Wainberg, MD, discusses the phase 3 DAWN-303 trial of INCB161734 plus chemotherapy and the expanding role of KRAS inhibitors in pancreatic cancer.

A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings

Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

Zev A. Wainberg, MD, discusses the mechanism of action of zanidatamab and its FDA approval as a new frontline option for HER2-positive gastric cancer.

Zev A. Wainberg, MD, discusses early-phase INCB161734 data in refractory pancreatic cancer and the evolving RAS inhibitor landscape.

A UCLA study found that traditional pathological features do not predict who will benefit more from adding hormone therapy to postoperative radiation. 

Jordyn Silverstein, MD, MSc, discusses updated data with abemaciclib plus hormonal therapy in ER-positive endometrial cancer and low-grade serous ovarian cancer.

Top experts discuss the most important takeaways and data in ovarian and endometrial cancer to come out of this year’s ASCO annual meeting.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

The FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation.

Rena D. Callahan, MD, discusses the clinical implications of the FDA approval of Dato-DXd for the treatment of patients with unresectable/metastatic TNBC.

Alexis Ann LeVee, MD, highlights breast cancer abstracts to pay attention to at the 2026 ASCO Annual Meeting.

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Rena D. Callahan, MD, discusses the clinical utility and shifting paradigms of oral SERDs for patients with ER-positive advanced breast cancer.

Rena D. Callahan, MD, discusses questions regarding treatment sequencing with CDK4/6 inhibitors and ADCs in hormone receptor–positive breast cancer.

Rena D. Callahan, MD, notes the implications of adding camizestrant to an aromatase inhibitor in ER-positive breast cancer with an emergent ESR1 mutation.

Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer.

A new UCLA study suggests the organization of immune cells inside melanoma tumors may help show which patients benefit from combination immunotherapy

Low-cost blood tests that detect multiple blood cancers and diseases have been developed by researchers at UCLA Health.